Daily Stock Analysis, ARQL, ArQule Inc, priceseries

ArQule Inc. Daily Stock Analysis
Stock Information
Open
3.31
Close
3.30
High
3.35
Low
3.20
Previous Close
3.31
Daily Price Gain
-0.01
YTD High
4.13
YTD High Date
Jan 16, 2019
YTD Low
2.70
YTD Low Date
Jan 2, 2019
YTD Price Change
0.41
YTD Gain
14.19%
52 Week High
7.21
52 Week High Date
Jul 9, 2018
52 Week Low
1.63
52 Week Low Date
Mar 5, 2018
52 Week Price Change
1.51
52 Week Gain
84.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 29. 2017
1.06
Sep 12. 2017
1.13
9 Trading Days
6.98%
Link
LONG
Nov 8. 2017
1.10
Dec 12. 2017
1.45
23 Trading Days
31.89%
Link
LONG
Mar 6. 2018
1.73
Apr 6. 2018
2.89
22 Trading Days
67.13%
Link
LONG
May 10. 2018
2.72
Jun 15. 2018
5.04
25 Trading Days
85.43%
Link
Company Information
Stock Symbol
ARQL
Exchange
NasdaqGM
Company URL
http://www.arqule.com
Company Phone
781-994-0300
CEO
Paolo Pucci
Headquarters
Massachusetts
Business Address
ONE WALL STREET, BURLINGTON, MA 01803
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001019695
About

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its proprietary pipeline is directed towards molecular targets and biological processes with demonstrated roles in the development of human cancers. Its portfolio includes Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. The company was founded in 1993 and is headquartered in Burlington, MA.

Description

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton's tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.